Fintech PR
Brussels Workshop Explores Challenges and Opportunities in the 4th Industrial Revolution
On July 12, the CEIBS Insights 2019 Europe Forum series made its latest stop in Brussels for a special roundtable workshop on the theme of The 4th Industrial Revolution: Opportunities and Challenges for Europe and China. The event, co-hosted by European economic think tank Bruegel, brought together nearly 100 representatives from CEIBS, the European Commission, the Mission of the People’s Republic of China to the European Union, and the EFMD, among others, for discussions exploring how China and Europe can balance policy and market forces to achieve sustainable technological innovation, how SMEs in both regions can leverage opportunities to expand into overseas markets, and how both sides can work together to improve bilateral cooperation.
Charge d’Affaires ad interim for the Mission of the People’s Republic of China to the European Union Wang Hongjian, a representative of the Commissioner for Internal Market, Industry, Entrepreneurship and SMEs Ms. Elzbieta Bienkowskaand European Commission Deputy Director-General for Implementation, Impact & Sustainable Investment Strategies Mr. Patrick Child delivered keynote speeches at the event.
As CEIBS President and Professor of Management Li Mingjun noted in his welcome address, 2019 is a critical year for the Europe 2020 Strategy, and technological innovation is now crucial for sustaining Europe’s economic growth. As Chinafurther opens its doors to the outside world, he added, EU countries will discover new opportunities to take innovative technology from the lab to the market. “We look forward to establishing a foundation for communication with this forum,” Prof. Li said. “And to building a lasting and stable platform for the integration of innovation resources between China and the EU.”
Bruegel Director Dr. Guntram B. Wolff also welcomed participants to the event with a speech in which he noted the need to reflect together on current opportunities and challenges. He further added that the topic of the forum is important because “[it stands at] the intersection of new digital technologies, artificial intelligence and quantum computing, on the one hand, and industrial processes, on the other hand, and manufacturing processes. This interlinkage is at the core of the business model certainly of several economies in the EU, but also as the core of significant parts of the Chinese economy.”
Charge d’Affaires ad interim for the Mission of the People’s Republic of China to the European Union Wang Hongjian then offered a keynote speech on Innovation Cooperation Offers New Highlights in China-Europe Cooperation. In his speech, Mr. Wang emphasised that China and the EU should be more open and inclusive in their cooperation on innovation, should further align their innovation policies to achieve mutual benefits and should work to make long-term strategic plans. “Looking ahead, China and the EU are faced with shared challenges which will reshape the future of humankind, such as climate change, the new technology revolution, resources and environment challenges,” he stated. “China and the EU, as two major players, are duty-bound to join forces with a mind-set of reform and innovation, and to make a greater contribution to world peace, development and prosperity.”
CEIBS Distinguished Professor, Former World Trade Organisation Director-General and Notre Europe Honorary President Pascal Lamy continued with the next keynote speech of the event, in which he discussed the topic of Sino-EU Cooperation Under the New International Economic Order. In his speech, Prof. Lamy emphasised the point that, despite current challenges and uncertainties, there remains ample space for China and the EU to work together in areas of research and innovation. “We have a series of areas where we are already [involved in a lot of] cooperation, [including] food, agriculture, biotech, the environment and health,” he said. “So there are many reasons to move forward and enhance or foster and increase cooperation – many of them domestic and many global. This is how we should look at this picture.”
Bruegel Deputy Director Dr. Maria Demertzis moderated the first session of the day on the topic of Research and Innovation: Competition or Cooperation in the EU-China Context? Shanghai Institutes for International Studies President Chen Dongxiao, CEIBS Vice President and Dean Ding Yuan, and Bruegel Senior Fellow Prof. Reinhilde Veugelers participated in the panel discussion, in which they took an in-depth look at how “co-opetition” (or co-operative competition) in the development of new technologies is acting as a driving force for the 4th Industrial Revolution and how complementary priorities and strategies represent bright prospects for EU-China cooperation.
Following the luncheon, EFMD CEO and Director General Eric Cornuel traced the history of CEIBS to Brussels as “the Heart of Europe” and reviewed some of its world-renowned achievements in academic innovation over the past 25 years. “There is no doubt that innovation is a catalyst for growth built on the foundation of creative drive, co-operation and openness,” Prof. Cornuel said, adding later that, “China and Europe more than ever should get closer and create a favourable environment for innovation, growth and mutual understanding. No doubt CEIBS is an instrument of this co-operation.”
CEIBS Associate Dean (Research) and Professor of Economics and Finance Xu Bin then delivered a keynote speech on China’s Innovation Potential and Its Global Implication. In his speech, Prof. Xu noted that China’s investment in innovation has led to situation in which “it is inevitable that advanced countries will have direct competition with China.” At the same time, he said that the country’s development has resulted in increased demand for services imported to China and that companies seeking to maintain a competitive advantage “should make more effort to specialise in variety, in quality, and in brand.”
CEIBS Board of Directors Co-chairman and EFMD Honorary Chairman Dr. Gerard Van Schaik moderated the second session of the day, in which he invited participants to join a discussion on the theme of Industrial Approaches in Innovation Cooperation Between China and EU. Panellists featured China-EU Association President Luigi Gambardella; WINNER Technology Co., Inc. President and CEO Mr. Zhang Hongjun (CEIBS EMBA 2013); and DFKI Robotics Innovation Center Bremen Director Prof. Dr. Dr. h.c. Frank Kirchner. During the course of the discussion, participants shared their views on key drivers, incentives and best practices for innovation, and offered suggestions on how China and the EU can work both independently and collaboratively to foster innovation in the future.
Today’s event was co-organised by CEIBS and Bruegel, with support from the EU-China Business Association, the EFMD, Shanghai Institutes for International Studies and the Mission of the People’s Republic of China to the European Union, as is part of the CEIBS Insights 2019 Europe Forum series. The Europe Forum Series coincides with the on-going CEIBS 25th Anniversary Celebration and will wrap up in October with events in both Paris and London. For more details about these and other upcoming CEIBS events, please visit our events page here.
SOURCE China Europe International Business School (CEIBS)
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
“The Hainan FTP and Me”: Looking at Hainan’s Transformations
-
Latest News4 days ago
Millions of people unite around doing good on the 18th International Good Deeds Day held yesterday worldwide
-
Latest News4 days ago
Banxso Acquires Australian ASIC License, Enhancing Its Global Trading Operations
-
Latest News4 days ago
135th Canton Fair Launches a Showcase of Innovative Products of New Collection to Lead Global Market Trends
-
Latest News3 days ago
BMO Announces Election of Board of Directors
-
Latest News5 days ago
BII and FMO back BECIS with joint US$50 million financing facility supporting commercial and industrial renewables sector in South-East Asia
-
Latest News3 days ago
Fiat infrastructure Leader Banxa join forces with Venom foundation in offering Venom-supported tokens access to its global Fiat rails
-
Latest News5 days ago
Silent Eight secures AIA as its latest client